V1 sact_regimen
730,471 rows · 12 columns
| MERGED_REGIMEN_ID | MERGED_TUMOUR_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | MERGED_PATIENT_ID | BENCHMARK_GROUP |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 220007736 | 220003067 | 1.64 | null | null | null | 2013-03-01 | AML16 DA 3+10 | Y | N | 220033038 | AML16 TRIAL |
| 220007737 | 220003067 | 1.69 | 106 | Curative (C) | 2013-04-30 | 2013-04-30 | IDARUBICIN + TRETINOIN | N | N | 220033038 | IDARUBICIN + TRETINOIN |
| 220007738 | 220003067 | 1.6 | 46.2 | null | 2015-11-13 | 2015-11-14 | IDARUBICIN + TRETINOIN | N | N | 220033038 | IDARUBICIN + TRETINOIN |
| 220007739 | 220003068 | 1.6 | 62 | Curative (C) | 2014-11-20 | 2014-11-20 | AML18 PILOT TRIAL | null | null | 220033041 | PILOT TRIAL |
| 220007740 | 220003068 | 1.84 | null | Disease modification (D) | 2015-08-26 | 2015-08-26 | AML 18 Pilot Trial | 1 | N | 220033041 | PILOT TRIAL |
| 220007742 | 220003070 | null | 69.1 | Disease modification (D) | 2017-06-28 | 2017-06-28 | AML 18 TRIAL | 1 | null | 220033044 | AML18 TRIAL |
| 220007743 | 220011716 | 1.84 | null | Disease modification (D) | 2016-06-22 | 2016-06-22 | AML 18 Pilot Trial | Y | N | 220033049 | PILOT TRIAL |
| 220007744 | 220003071 | 1.77 | 92.8 | Disease modification (D) | 2015-06-18 | 2015-06-18 | Dasatinib | N | N | 220033054 | DASATINIB |
| 220007745 | 220011717 | 1.88 | 97 | Disease modification (D) | null | 2016-05-05 | AML16 DA 3+10 | N | N | 220033055 | AML16 TRIAL |
| 220007746 | 220011717 | 1.56 | 74.8 | Curative (C) | null | 2017-12-07 | IDARUBICIN + TRETINOIN | 99 | N | 220033055 | IDARUBICIN + TRETINOIN |
| 220007747 | 220011717 | null | 97 | Palliative (P) | 2014-01-04 | 2014-01-18 | GemCarbo Days 1+8 | N | null | 220033055 | GEMCARBO |
| 220007748 | 220011717 | null | 57 | Palliative (P) | 2013-05-14 | 2013-05-29 | GemCarbo Days 1+8 | N | null | 220033055 | GEMCARBO |
| 220007749 | 220011717 | 1.67 | 65.7 | Curative (C) | 2013-04-03 | 2013-04-25 | AML16 DA 3+10 | 02 | N | 220033055 | AML16 TRIAL |
| 220007750 | 220011717 | null | 123 | Palliative (P) | 2016-04-18 | 2016-04-25 | GEMCARBO | N | N | 220033055 | GEMCARBO |
| 220007751 | 220003072 | null | 54.4 | Disease modification (D) | 2017-02-04 | 2017-02-04 | Dasatinib | 02 | N | 220033067 | DASATINIB |
| 220007752 | 220003073 | 1.65 | 59.4 | Curative (C) | 2013-03-17 | 2013-03-17 | IDARUBICIN + TRETINOIN | N | N | 220033069 | IDARUBICIN + TRETINOIN |
| 220007753 | 220003074 | 1.88 | 90 | null | 2014-12-06 | 2014-12-06 | Idarubicin+Tretinoin Spanish Crse1 | 2 | N | 220033073 | IDARUBICIN + TRETINOIN |
| 220007754 | 220003074 | 1.77 | null | Palliative (P) | 2014-10-29 | 2014-11-12 | CARBOPLATIN + GEMCITABINE | null | N | 220033073 | GEMCARBO |
| 220007755 | 220003075 | null | null | Curative (C) | null | 2013-09-25 | AML18 PILOT TRIAL | 1 | N | 220033075 | PILOT TRIAL |
| 220007756 | 220011719 | 1.73 | 64.5 | Curative (C) | 2013-10-02 | 2013-10-02 | Idarubicin+Tretinoin Spanish Crse1 | Y | N | 220033078 | IDARUBICIN + TRETINOIN |
| 220007757 | 220011719 | 1.69 | 72 | Curative (C) | 2013-08-25 | 2013-08-30 | AML18 PILOT TRIAL | Y | N | 220033078 | PILOT TRIAL |
| 220007758 | 220018930 | 1.69 | 81.3 | Palliative (P) | 2015-11-30 | 2016-01-16 | Cisplatin+Gemcitabine (gallbladder) | 2 | N | 220033081 | CISPLATIN + GEMCITABINE |
| 220007759 | 220003076 | 1.67 | 94.7 | null | 2013-10-09 | 2013-10-25 | GEMCARBO | 02 | null | 220033083 | GEMCARBO |
| 220007761 | 220003078 | 1.6 | 73.8 | null | 2013-05-24 | 2013-05-30 | Cisplatin + Gemcitabine (D 1 & 8) | N | null | 220033086 | CISPLATIN + GEMCITABINE |
| 220007762 | 220003079 | 1.73 | 59.7 | null | 2014-04-24 | 2014-05-08 | GEMCARBO | N | N | 220033087 | GEMCARBO |
| 220007763 | 220003079 | 1.51 | null | Curative (C) | 2013-01-30 | 2013-02-20 | AML 18 TRIAL | 1 | N | 220033087 | AML18 TRIAL |
| 220007764 | 220003080 | 1.74 | null | Curative (C) | 2014-03-11 | 2014-03-11 | Idarubicin+Tretinoin Spanish Crse4 | N | N | 220033090 | IDARUBICIN + TRETINOIN |
| 220007765 | 220003081 | 1.58 | 44.8 | Curative (C) | 2017-03-23 | 2017-04-01 | Carboplatin + Paclitaxel (3 weekly) | 02 | N | 220033093 | CARBOPLATIN + PACLITAXEL |
| 220007769 | 220016307 | 1.68 | 66.15 | Palliative (P) | 2017-07-04 | 2017-07-04 | Cisplatin + Gemcitabine (D 1 & 8) | null | N | 220033104 | CISPLATIN + GEMCITABINE |
| 220007770 | 220016307 | 1.83 | 52.7 | null | 2016-06-16 | 2016-06-23 | GEMCARBO | N | N | 220033104 | GEMCARBO |
| 220007771 | 220016307 | 1.82 | 78.1 | Curative (C) | 2014-04-07 | 2014-04-07 | AML18 PILOT TRIAL | N | N | 220033104 | PILOT TRIAL |
| 220007772 | 220016307 | 1.65 | 51 | Palliative (P) | 2013-07-09 | 2013-07-12 | Dasatinib | N | N | 220033104 | DASATINIB |
| 220007773 | 220003084 | 1.63 | 111.5 | Disease modification (D) | 2016-09-18 | 2016-09-28 | AML16 DA 3+10 | N | N | 220033114 | AML16 TRIAL |
| 220007774 | 220003084 | 1.61 | 82.1 | Curative (C) | null | 2013-12-02 | AML16 DA 3+8 | N | N | 220033114 | AML16 TRIAL |
| 220007775 | 220003085 | 1.63 | 81 | Curative (C) | 2013-03-31 | 2013-03-31 | IDARUBICIN + TRETINOIN | null | N | 220033117 | IDARUBICIN + TRETINOIN |
| 220007776 | 220003086 | 1.85 | 69.3 | Palliative (P) | 2017-08-14 | 2017-08-16 | AML16 DA 3+10 | N | N | 220033121 | AML16 TRIAL |
| 220007777 | 220003087 | 1.85 | 86 | Curative (C) | 2016-07-29 | 2016-07-29 | AML16 Low Dose Cytarabine | 02 | N | 220033122 | AML16 TRIAL |
| 220007778 | 220003088 | 1.75 | 88.2 | Curative (C) | 2016-06-28 | 2016-07-10 | AML 18 TRIAL | 01 | N | 220033123 | AML18 TRIAL |
| 220007782 | 220003089 | null | 54 | Curative (C) | null | 2013-06-13 | AML 18 TRIAL | Y | null | 220033130 | AML18 TRIAL |
| 220007783 | 220003090 | 1.63 | 114 | Curative (C) | 2017-05-13 | 2017-05-13 | Idarubicin+Tretinoin Spanish Crse1 | N | N | 220033132 | IDARUBICIN + TRETINOIN |
| 220007784 | 220003090 | 1.83 | 76 | Curative (C) | 2013-11-03 | 2013-11-03 | AML18 PILOT TRIAL | 1 | N | 220033132 | PILOT TRIAL |
| 220007785 | 220003090 | null | 74.7 | Palliative (P) | 2017-09-22 | 2017-11-02 | Cisplatin+Gemcitabine (gallbladder) | 02 | N | 220033132 | CISPLATIN + GEMCITABINE |
| 220007786 | 220003090 | null | null | Curative (C) | 2016-01-04 | 2016-01-05 | AML18 PILOT TRIAL | Y | N | 220033132 | PILOT TRIAL |
| 220007787 | 220003091 | 1.58 | 74.3 | Curative (C) | 2017-08-22 | 2017-08-26 | AML18 PILOT TRIAL | Y | N | 220033141 | PILOT TRIAL |
| 220007788 | 220003092 | null | 84 | Curative (C) | 2015-04-08 | 2015-04-08 | AML 18 TRIAL | 1 | N | 220033144 | AML18 TRIAL |
| 220007789 | 220003093 | 1.74 | 99.8 | Palliative (P) | 2017-10-20 | 2017-10-20 | Cisplatin + Gemcitabine (D 1 & 8) | N | null | 220033145 | CISPLATIN + GEMCITABINE |
| 220007790 | 220003094 | 1.87 | 79 | null | 2014-11-01 | 2014-11-01 | Dasatinib | 02 | N | 220033147 | DASATINIB |
| 220007791 | 220003095 | 1.67 | 113 | null | null | 2013-02-14 | AML16 DA 3+8 | N | N | 220033149 | AML16 TRIAL |
| 220007795 | 220020442 | null | 69.5 | Curative (C) | 2016-06-28 | 2016-06-28 | AML18 PILOT TRIAL | N | N | 220033159 | PILOT TRIAL |
| 220007796 | 220020442 | 1.68 | 72.6 | Adjuvant (A) | 2017-09-11 | 2017-09-14 | AML 18 TRIAL | 1 | N | 220033159 | AML18 TRIAL |